US20080146783A1 - Method for the purification of albumin conjugates - Google Patents

Method for the purification of albumin conjugates Download PDF

Info

Publication number
US20080146783A1
US20080146783A1 US11/981,474 US98147407A US2008146783A1 US 20080146783 A1 US20080146783 A1 US 20080146783A1 US 98147407 A US98147407 A US 98147407A US 2008146783 A1 US2008146783 A1 US 2008146783A1
Authority
US
United States
Prior art keywords
seq id
mpa
lys
conh
ε
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/981,474
Inventor
Nathalie Bousquet-Gagnon
Omar Quraishi
Dominique P. Bridon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4523482 CANADA Inc
Conjuchem LLC
Original Assignee
ConjuChem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US56522804P priority Critical
Priority to US11/112,277 priority patent/US7307148B2/en
Application filed by ConjuChem Biotechnologies Inc filed Critical ConjuChem Biotechnologies Inc
Priority to US11/981,474 priority patent/US20080146783A1/en
Publication of US20080146783A1 publication Critical patent/US20080146783A1/en
Assigned to CONJUCHEM BIOTECHNOLOGIES, INC. reassignment CONJUCHEM BIOTECHNOLOGIES, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: 4523482 CANADA INC.
Assigned to 4523482 CANADA INC reassignment 4523482 CANADA INC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CONJUCHEM BIOTECHNOLOGIES INC. (CANADIAN CORPORATION NUMBER 6513590)
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35196920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080146783(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Assigned to ADVANCED DIAGNOSTICS AND DISCOVERY reassignment ADVANCED DIAGNOSTICS AND DISCOVERY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CONJUCHEM BIOTECHNOLOGIES INC.
Assigned to CONJUCHEM, LLC reassignment CONJUCHEM, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ADVANCED DIAGNOSTICS AND DISCOVERY
Application status is Abandoned legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/30Extraction; Separation; Purification by precipitation
    • C07K1/303Extraction; Separation; Purification by precipitation by salting out
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32Bonded phase chromatography
    • B01D15/325Reversed phase
    • B01D15/327Reversed phase with hydrophobic interaction
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/20Partition-, reverse-phase or hydrophobic interaction chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/10Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/166Fluid composition conditioning, e.g. gradient
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/42Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424Elution mode
    • B01D15/426Specific type of solvent

Abstract

The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the support a gradient of decreasing salt concentration; and collecting the eluted albumin conjugate.

Description

    RELATED APPLICATION
  • This application claims priority to U.S. provisional patent application Ser. No. 60/565,228 filed Apr. 23, 2004, which is expressly incorporated by reference in its entirety.
  • BACKGROUND OF THE INVENTION
  • (a) Field of the Invention
  • This invention relates to a method of purification for isolating albumin conjugates from a solution comprising both albumin conjugates and unconjugated albumin.
  • (b) Description of Prior Art
  • WO 95/10302 and WO 99/24074 describe the formation of conjugates of albumin wherein the molecule of interest has a reactive functionality coupled thereto that is adapted to covalently bond to albumin, thus forming a conjugate. These conjugates can be formed in vivo, but they can be formed in vitro as well. The formation of the conjugate in vitro involves the addition of a molecule coupled to a reactive functionality to a solution of albumin. The primary end products from this reaction are unconjugated albumin, the albumin conjugate and the unreacted molecule coupled to the reactive functionality.
  • It would be highly desirable to be provided with a method for purifying albumin conjugate from a solution comprising albumin conjugate and unconjugated albumin.
  • SUMMARY OF THE INVENTION
  • In accordance with the present invention there is provided a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin, the method comprising:
  • a) loading the solution onto a hydrophobic solid support equilibrated in aqueous buffer having a high salt content;
    b) applying to the support a gradient of decreasing salt content; and
    c) collecting eluted albumin conjugate.
  • In a preferred embodiment of the present invention, the albumin conjugate consists of a molecule having a Michael acceptor covalently coupled thereto which bonds to albumin, and more preferably the bond is between the Michael acceptor and cysteine 34 of albumin.
  • In a more preferred embodiment of the present invention, the Michael acceptor is a maleimide group, and more preferably, the maleimide group is maleimide-propionic acid (MPA). The Michael acceptor is optionally coupled to the molecule via a linker. The linker is preferably selected in the group consisting of hydroxyethyl motifs such as (2-amino) ethoxy acetic acid (AEA), ethylenediamine (EDA), 2-[2-(2-amino)ethoxy)]ethoxy acetic acid (AEEA), amino ethoxy ethyl amino succinic acid (AEEAS); one or more alkyl chains (C1-C10) motifs such as glycine, 3-aminopropionic acid (APA), 8-aminooctanoic acid (AOA), octanoic acid (OA), 4-aminobenzoic acid (APhA). Preferred linkers are OA, ADE, AEA, AEEA and AEEAS. A combination of two linkers can also be used such as, for examples, AEEA-EDA, AEEA-AEEA, AEEAS-AEEAS, and AEA-AEEA.
  • In a preferred embodiment of the present invention, the albumin is selected from the group consisting of serum albumin, recombinant albumin and albumin from a genomic source.
  • In a preferred embodiment of the present invention, the albumin is selected from the group consisting of human albumin, rat albumin, mouse albumin, swine albumin, bovine albumin, dog albumin and rabbit albumin, more preferable human serum albumin.
  • In a preferred embodiment, albumin is modified with at least one selected from the group consisting of fatty acids, metal ions, small molecules having high affinity to albumin, and sugars, such as, but not limited to, glucose, lactose and mannose.
  • In a preferred embodiment of the present invention, the molecule is selected from the group consisting of a peptide, DNA, RNA, small organic molecule and a combination thereof. The peptide has preferentially a molecular weight of at least 57 daltons. The peptide is intended to include, but not being limited to, GLP-1, GLP-2, ANP, K5, dynorphin, GRF, insulin, natriuretic peptides, T-20, T-1249, C-34 and PYY. The small molecule is intended to include, but not being limited to, vinorelbine, gemcitabine and paclitaxel. In a more preferred embodiment of the present invention, when the molecule is a DNA, RNA or a small organic molecule, it is covalently attached to the albumin through an acid sensitive covalent bond or a peptide sequence susceptible to proteolytic cleavage, thereby allowing the separation of the molecule from albumin and the entry of the molecule into a cell.
  • In a preferred embodiment of the present invention, the hydrophobic solid support is a column containing a hydrophobic resin such as, but not limited to, octyl sepharose, phenyl sepharose and butyl sepharose and more preferably butyl sepharose.
  • In another embodiment of the present invention, the hydrophobic solid support comprising a hydrophobic ligand such as Cibacron Blue F3G-A, ether or isopropyl groups in association with a support such as polystyrene/divinyl benzene matrix.
  • Substances are separated on the basis of their varying strengths of hydrophobic interactions with hydrophobic ligands immobilized to an uncharged matrix. This technique is usually performed with moderately high concentrations of salts (≈1M) in the start buffer (salt promoted adsorption). Elution is achieved by a linear or stepwise decrease in salt concentration.
  • The type of ligand, the degree of substitution, the pH and the type and concentration of salt used during the adsorption stage have a profound effect on the overall performance (e.g. selectivity and capacity) of a HIC matrix (Hydrophobic Interaction Chromatography matrix).
  • The solvent is one of the most important parameters which influence capacity and selectivity in HIC (Hydrophobic Interaction Chromatography). In general, the adsorption process is more selective than the desorption process. It is therefore important to optimize the start buffer with respect to pH, type of solvent, type of salt and concentration of salt. The addition of various “salting-out” salts to the sample promotes ligand-protein interactions in HIC. As the concentration of salt is increased, the amount of bound protein increases up to the precipitation point for the protein. Each type of salt differs in its ability to promote hydrophobic interactions. The influence of different salts on hydrophobic interaction follows the well-known Hofmeisters series found below:
  • Hofmeisters Series Salting-Out Effect Anions:
  • PO4 3−>SO4 2−>CH3COO>Cl>Br>NO3 >ClO4 >I>SCN
  • Chaotropic Effect Cations: NH4 +<Rb+<K+<Na+<Cs+<Li+<Mg2+<Ba2+
  • Increasing the salting-out effect strengthens the hydrophobic interactions, whereas increasing the chaotropic effect weakens them. Therefore, ammonium sulfate exhibits a stronger salting-out effect than sodium chloride. The most commonly used salts for HIC are ammonium sulfate ((NH4)2SO4), sodium sulfate ((Na)2SO4)), magnesium sulfate (MgSO4), sodium chloride (NaCl), potassium chloride (KCl), and ammonium acetate (CH3COONH4).
  • Protein binding to HIC adsorbents is promoted by moderate to high concentrations of “salting-out” salts, most of which also have a stabilizing influence on protein structure due to their preferential exclusion from native globular proteins, i.e. the interaction between the salt and the protein surface is thermodynamically unfavorable. The salt concentration should be high enough (e.g. 500-1000 mM) to promote ligand-protein interactions yet below that which causes precipitation of the protein in the sample. In the case of albumin, the salt concentration should be kept below 3M (moles per liter). The principle mechanism of salting-out consists of the salt-induced increase of the surface tension of water (Melander and Horváth, 1977). Thus, a compact structure becomes energetically more favorable because it corresponds to smaller protein-solution interfacial area.
  • Interestingly, we found that under the same conditions (i.e. buffer composed of SO4 2−, PO4 2− or CH3COOwith any counter ion), these salts exhibit their salting-out effect upon essentially all conjugated albumin described herein in a manner different to non-conjugated albumin (i.e. mercaptalbumin and albumin capped with cysteine), thus enabling a consistent chromatographic separation between conjugated albumin versus non-conjugated albumin. That is, we observe that lower concentrations of salt are required to promote interactions between ligand and conjugated albumin than between ligand and non-conjugated albumin. This chromatographic separation is essentially independent of (a) the sequence of albumin (e.g. human, mouse, rat, etc.) (b) the source of albumin (i.e. plasma derived or recombinant) (c) the molecular weight of the conjugated molecule, (d) the position of the Michael acceptor (or maleimide group) within the structure of the molecule, (e) the peptide sequence or chemical structure of the molecule, and (f) the three-dimensional structure of the conjugated molecule, e.g. linear versus loop structure.
  • In a preferred embodiment of the present invention, the salt of the aqueous buffer has a sufficient salting out effect. For providing a sufficient salting out effect, the salt is preferably, but not limited to, phosphate, sulfate and acetate. More preferably, the salt is phosphate or sulfate. The selection of the cation of the buffer is less critical and therefore, such cation can be selected, without limitation, from the group consisting of NH4 +, Rb+, K+, Na+, Cs+, Li+, Mg2+ and Ba2+.
  • The aqueous buffer is preferably ammonium phosphate, ammonium sulfate and magnesium phosphate, and more preferably ammonium sulfate.
  • In a preferred embodiment of the present invention, the buffer pH is between 3.0 and 9.0; more preferably between 6.0 and 8.0, and even more preferably, the pH is 7.0.
  • In a preferred embodiment of the present invention, the buffer and the hydrophobic solid support are at room temperature (about 25° C.) or at 4° C. or in between.
  • Table 1 shows an example of the effect of varying salts for purification of preformed HSA:first GLP-1 analogue conjugate from a solution of HSA using butyl-sepharose resin (structure of the first GLP-1 analogue is described in Example 1 below).
  • TABLE 1
    Starting salt Starting salt
    concentration of concentration of
    Salt type 750 mM 1,750 mM
    Ammonium phosphate Yes yes
    Ammonium sulfate Yes yes
    Ammonium chloride No no
    Ammonium iodide No no
    Ammonium thiocyanate No no
    Magnesium sulfate No yes
    Magnesium phosphate*
    Barium sulfate*
    *means that the salt is not soluble at concentrations of 1750 mM or 750 mM in 20 mM sodium phosphate (pH 7), 5 mM caprylate
    Yes means that successful resolution is achieved between the HSA:first GLP-1 analogue conjugate and the non-conjugated HSA
    No means that no separation is achieved between the HSA:first GLP-1 analogue conjugate and the non-conjugated HSA
  • The term “peptide” is intended to mean an amino acid sequence having a molecular weight of at least 57 daltons. The peptidic sequence can be circular (loop structure) such as ANP, may contain more than one amino acid chain such as insulin or may be linear such as K5, dynorphin A, C-34 and GLP-1.
  • All references herein are hereby incorporated by reference.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 illustrates the purification of the conjugate HSA:first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;
  • FIG. 2 illustrates the purification of the conjugate HSA:first GRF analogue (SEQ ID NO:2) by a preferred embodiment of the method of the present invention;
  • FIG. 3 illustrates the purification of non-conjugated HSA by a preferred embodiment of the method of the present invention;
  • FIG. 4 illustrates the purification of the conjugate rHSA:first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;
  • FIG. 5 illustrates the purification of HSA cortex by a preferred embodiment of the method of the present invention;
  • FIG. 6 illustrates the purification of the conjugate HSA:K5 analogue (SEQ ID NO:3) by a preferred embodiment of the method of the present invention;
  • FIG. 7 illustrates the purification of the conjugate HSA:first insulin derivative (SEQ ID NO:4) by a preferred embodiment of the method of the present invention;
  • FIG. 8 illustrates the purification of the conjugate HSA:second insulin derivative (SEQ ID NO:5) by a preferred embodiment of the method of the present invention;
  • FIG. 9 illustrates the purification of the conjugate HSA:first C34 analogue (SEQ ID NO:6) by a preferred embodiment of the method of the present invention;
  • FIG. 10 illustrates the purification of the conjugate HSA:second C34 analogue (SEQ ID NO:7) by a preferred embodiment of the method of the present invention;
  • FIG. 11 illustrates the purification of the conjugate HSA:third C34 analogue (SEQ ID NO:8) by a preferred embodiment of the method of the present invention;
  • FIG. 12 illustrates the purification of L-cysteine by a preferred embodiment of the method of the present invention;
  • FIG. 13 illustrates the purification of L-cysteine:first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;
  • FIG. 14 illustrates the purification of the conjugate HSA:second GLP-1 analogue (SEQ ID NO:9) by a preferred embodiment of the method of the present invention;
  • FIG. 15 illustrates the purification of the conjugate HSA:third GLP-1 analogue (SEQ ID NO:10) by a preferred embodiment of the method of the present invention;
  • FIG. 16 illustrates the purification of the conjugate HSA:fourth GLP-1 analogue (SEQ ID NO:11) by a preferred embodiment of the method of the present invention;
  • FIG. 17 illustrates the purification of the conjugate HSA:fifth GLP-1 analogue (SEQ ID NO:12) by a preferred embodiment of the method of the present invention;
  • FIG. 18 illustrates the purification of the conjugate HSA:first Exendin-4 analogue (SEQ ID NO:13) by a preferred embodiment of the method of the present invention;
  • FIG. 19 illustrates the purification of the conjugate HSA:second Exendin-4 analogue (SEQ ID NO:14) by a preferred embodiment of the method of the present invention;
  • FIG. 20 illustrates the purification of HSA:MPA by a preferred embodiment of the method of the present invention;
  • FIG. 21 illustrates the purification of HSA by a preferred embodiment of the method of the present invention;
  • FIG. 22 illustrates the purification of the conjugate HSA:second C34 analogue (SEQ ID NO:3) by a preferred embodiment of the method of the present invention;
  • FIG. 23 illustrates the purification of the conjugate HSA:first Dynorphin A analogue (SEQ ID NO:15) by a preferred embodiment of the method of the present invention;
  • FIG. 24 illustrates the purification of the conjugate HSA:first ANP analogue (SEQ ID NO:16) by a preferred embodiment of the method of the present invention;
  • FIG. 25 illustrates the purification of the conjugate HSA:second Dynorphin A analogue (SEQ ID NO:17) by a preferred embodiment of the method of the present invention;
  • FIG. 26 illustrates the purification of the conjugate HSA:ACE inhibitor (SEQ ID NO:18) by a preferred embodiment of the method of the present invention;
  • FIG. 27 illustrates the purification of the conjugate HSA:sixth GLP-1 analogue (SEQ ID NO:19) by a preferred embodiment of the method of the present invention;
  • FIG. 28 illustrates the purification of the conjugate HSA:seventh GLP-1 analogue (SEQ ID NO:20) by a preferred embodiment of the method of the present invention;
  • FIG. 29 illustrates the purification of the conjugate HSA:eighth GLP-1 analogue (SEQ ID NO:21) by a preferred embodiment of the method of the present invention;
  • FIG. 30 illustrates the purification of the conjugate HSA:ninth GLP-1 analogue (SEQ ID NO:22) by a preferred embodiment of the method of the present invention;
  • FIG. 31 illustrates the purification of the conjugate HSA:tenth GLP-1 analogue (SEQ ID NO:23) by a preferred embodiment of the method of the present invention;
  • FIG. 32 illustrates the purification of the conjugate HSA:eleventh GLP-1 analogue (SEQ ID NO:24) by a preferred embodiment of the method of the present invention;
  • FIG. 33 illustrates the purification of the conjugate HSA:third Exendin-4 analogue (SEQ ID NO:25) by a preferred embodiment of the method of the present invention;
  • FIG. 34 illustrates the purification of the conjugate HSA:twelfth GLP-1 analogue (SEQ ID NO:26) by a preferred embodiment of the method of the present invention;
  • FIG. 35 illustrates the purification of the conjugate HSA:first insulin derivative (SEQ ID NO:4) by a preferred embodiment of the method of the present invention;
  • FIG. 36 illustrates the purification of the conjugate HSA:third insulin derivative (SEQ ID NO:27) by a preferred embodiment of the method of the present invention;
  • FIG. 37 illustrates the purification of the conjugate HSA:second insulin derivative (SEQ ID NO:5) by a preferred embodiment of the method of the present invention;
  • FIG. 38 illustrates the purification of the conjugate HSA:fourth insulin derivative (SEQ ID NO:28) by a preferred embodiment of the method of the present invention;
  • FIG. 39 illustrates the purification of the conjugate HSA:first GRF analogue (SEQ ID NO:2) by a preferred embodiment of the method of the present invention;
  • FIG. 40 illustrates the purification of the conjugate HSA:second GRF analogue (SEQ ID NO:29) by a preferred embodiment of the method of the present invention;
  • FIG. 41 illustrates the purification of the conjugate HSA:third GRF analogue (SEQ ID NO:30) by a preferred embodiment of the method of the present invention;
  • FIG. 42 illustrates the purification of the conjugate HSA:fourth GRF analogue (SEQ ID NO:31) by a preferred embodiment of the method of the present invention;
  • FIG. 43 illustrates the purification of the conjugate HSA:thirteenth GLP-1 analogue CJC 1365 (SEQ ID NO:32) by a preferred embodiment of the method of the present invention;
  • FIG. 44 illustrates the purification of the conjugate HSA lactose:first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;
  • FIG. 45 illustrates the purification of the conjugate HSA:first T20 analogue (SEQ ID NO:33) by a preferred embodiment of the method of the present invention;
  • FIG. 46 illustrates the purification of the conjugate HSA:first T1249 analogue (SEQ ID NO:34) by a preferred embodiment of the method of the present invention;
  • FIG. 47 illustrates the purification of the compound HSA:first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;
  • FIG. 48 illustrates the purification of the compound HSA:first C34 analogue (SEQ ID NO:6) by a preferred embodiment of the method of the present invention;
  • FIG. 49 illustrates the purification of the compound HSA:second GRF analogue (SEQ ID NO:29) by a preferred embodiment of the method of the present invention;
  • FIG. 50 illustrates the purification of the conjugate HSA:vinorelbine analogue conjugate (SEQ ID NO:35) by a preferred embodiment of the method of the present invention;
  • FIG. 51 illustrates the purification of L-cysteine by a preferred embodiment of the method of the present invention;
  • FIG. 52 illustrates the purification of the conjugate L-Cysteine:vinorelbine analogue (SEQ ID NO:35) by a preferred embodiment of the method of the present invention;
  • FIG. 53 illustrates the purification of the conjugate RSA:third Exendin-4 analogue (SEQ ID NO:25) by a preferred embodiment of the method of the present invention;
  • FIG. 54 illustrates the purification of the conjugate HSA:fourth C34 analogue (SEQ ID NO:36) by a preferred embodiment of the method of the present invention;
  • FIG. 55 illustrates the purification of the conjugate HSA:fifth C34 analogue (SEQ ID NO:37) by a preferred embodiment of the method of the present invention;
  • FIG. 56 illustrates the purification of the conjugate HSA:sixth C34 analogue (SEQ ID NO:38) by a preferred embodiment of the method of the present invention;
  • FIG. 57 illustrates the purification of the conjugate HSA:seventh C34 analogue (SEQ ID NO:39) by a preferred embodiment of the method of the present invention;
  • FIG. 58 illustrates the purification of the conjugate HSA:eighth C34 analogue (SEQ ID NO:40) by a preferred embodiment of the method of the present invention;
  • FIG. 59 illustrates the purification of the conjugate HSA:first PYY analogue (SEQ ID NO:41) by a preferred embodiment of the method of the present invention;
  • FIG. 60 illustrates the purification of the conjugate HSA:second PYY analogue (SEQ ID NO:42) by a preferred embodiment of the method of the present invention;
  • FIG. 61 illustrates the purification of the conjugate HSA:fifth insulin derivative (SEQ ID NO:43) by a preferred embodiment of the method of the present invention;
  • FIG. 62 illustrates the purification of the conjugate HSA:sixth insulin derivative (SEQ ID NO:44) by a preferred embodiment of the method of the present invention;
  • FIG. 63 illustrates the purification of the conjugate HSA:seventh insulin derivative (SEQ ID NO:45) by a preferred embodiment of the method of the present invention;
  • FIG. 64 illustrates the purification of the conjugate HSA:third PYY analogue (SEQ ID NO:46) by a preferred embodiment of the method of the present invention;
  • FIG. 65 illustrates the purification of the conjugate HSA:fourth PYY analogue (SEQ ID NO:47) by a preferred embodiment of the method of the present invention;
  • FIG. 66 illustrates the purification of the conjugate HSA:fifth PYY analogue (SEQ ID NO:48) by a preferred embodiment of the method of the present invention;
  • FIG. 67 illustrates the purification of the conjugate HSA:sixth PYY analogue (SEQ ID NO:49) by a preferred embodiment of the method of the present invention;
  • FIG. 68 illustrates the purification of the conjugate HSA:second ANP analogue (SEQ ID NO:50) by a preferred embodiment of the method of the present invention;
  • FIGS. 69A-B illustrates the purification of the conjugate HSA:third ANP analogue CJC 1681 (SEQ ID NO:51) by a preferred embodiment of the method of the present invention;
  • FIG. 70 illustrates the purification of the conjugate HSA:first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;
  • FIG. 71 illustrates the purification of the conjugate HSA:first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;
  • FIG. 72 illustrates the purification of the conjugate HSA:first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;
  • FIG. 73 illustrates the purification of the conjugate HSA:first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;
  • FIG. 74 illustrates the purification of the conjugate HSA:first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;
  • FIG. 75 illustrates the purification of the conjugate HSA:first GLP-2 analogue (SEQ ID NO:52) by a preferred embodiment of the method of the present invention; and
  • FIG. 76 illustrates the purification of the conjugate RSA:first GLP-2 analogue (SEQ ID NO:52) by a preferred embodiment of the method of the present invention.
  • DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT OF THE INVENTION
  • In accordance with the present invention, there is provided a method for purifying albumin conjugates from a solution comprising albumin conjugates and unconjugated albumin.
  • Methods Preparation of Control (Non-Conjugated) Human Serum Albumin (HSA) and Preformed Albumin Conjugates
  • Each compound with the Michael acceptor was solubilized in nanopure water (or in DMSO if the compound was difficult to solubilize) at a concentration of 10 mM, then diluted to 1 mM into a solution of HSA (25%, 250 mg/ml, Cortex-Biochem, San Leandro, Calif.). The samples were then incubated at 37° C. for 30 min. Prior to their purification, each conjugate solution was diluted to 5% 50 mg/ml HSA in 20 mM sodium phosphate buffer (pH 7) composed of 5 mM sodium octanoate. The initial concentration of salt used in the elution gradient can be added to the buffer for diluting the mixed solution. Preferably, the initial concentration of salt is from about 750 to about 1700 mM (NH4)2SO4.
  • Procedure for Purification According to a Preferred Embodiment
  • Using an
    Figure US20080146783A1-20080619-P00001
    KTA purifier (Amersham Biosciences, Uppsala, Sweden), each conjugate was loaded at a flow rate of 2.5 ml/min onto a 50 ml column of butyl sepharose 4 fast flow resin (Amershan Biosciences, Uppsala, Sweden) equilibrated in 20 mM sodium phosphate buffer (pH 7) composed of 5 mM sodium octanoate and 750 mM to 1.7 M (NH4)2SO4. Under these conditions, HSA conjugates having a molecular weight addition of more than 2 kDa relative to non-conjugated HSA adsorbed onto the hydrophobic resin whereas essentially all non-conjugated HSA eluted within the void volume of the column. For molecular weight additions of less than 2 kDa, a higher initial salt content may be used followed by a stepwise gradient of decreasing salt. Each conjugate was further purified from any free unconjugated compound by applying a continuous or non-continuous decreasing gradient of salt (750 to 0 mM (NH4)2SO4) over 4 column volumes. In a preferred embodiment, each purified conjugate was then desalted and concentrated by diafiltration, for instance by using Amicon® ultra centrifugal (30 kDa) filter devices (Millipore Corporation, Bedford, Mass.). Finally, for prolonged storage, each conjugate solution is preferably immersed into liquid nitrogen, and lyophilized using a Labconco freeze dry system (FreeZone®4.5), and stored at −20° C.
  • Examples of LC/EMS Analysis
  • Following purification, 1 μl of each conjugate sample is preferably injected onto LC/EMS system. The HSA:first GLP-1 analogue (SEQ ID NO:1) conjugate was confirmed by detection of a species of highest abundance with a total mass of 70 160 Da which corresponds to the mass of mercaptalbumin (66 448 Da) where cysteine 34 is in the free thiol form, plus the mass of only one molecule of the first GLP-1 analogue (3 719.9 Da). The structure of the first GLP-1 analogue (SEQ ID NO:1) is described in Example 1 below. This is illustrated in Table 2.
  • TABLE 2
    Molecular Absolute Relative
    Component Weight Abundance Abundance
    A 70160.58 321970 100.00
    B 65862.95 70008 21.74
    C 64545.45 62888 19.53
    D 70320.04 41167 12.79
    E 61287.67 16842 5.23
    F 60623.81 16522 5.13
    G 58090.04 12473 3.87
  • The HSA:first GRF analogue (SEQ ID NO:2) conjugate was confirmed by detection of a species of highest abundance with a total mass of 70 086 Da which corresponds to the mass of mercaptalbumin (66 448 Da) where cysteine 34 is in the free thiol form, plus the mass of only one molecule of the first GRF analogue (3648.2 Da). The structure of the first GRF analogue (SEQ ID NO:2) is described in Example 2 below. This is illustrated in Table 3.
  • TABLE 3
    Molecular Absolute Relative
    Component Weight Abundance Abundance
    A 70086.06 279413 100.00
    B 63214.84 53333 19.09
    C 62148.17 38582 13.81
    D 70247.98 34870 12.48
    E 56795.96 10523 3.77
    F 62695.49 9813 3.51
  • The following examples illustrate several compounds having a maleimide group as Michael acceptor that have been conjugated to albumin and purified in accordance with the method of the present invention.
  • The following examples are for the purpose of illustrating the present invention and not of limiting its scope.
  • In the following examples, the gradient numbers refer to the following gradient details, where CV means a column volume of 50 ml.
  • Gradient #1: Linear 750-0 mM (NH4)2SO4, over 4 CV, flow rate of 2.5 ml/min.
  • Gradient #2: Step gradient 1.75M-1.2M (NH4)2SO4 over 0.5 CV, followed by 1.2M-875 mM (NH4)2SO4 over 5 CV, and finally 875 mM-0 mM (NH4)2SO4 over 0.5 CV flow rate of 2.5 ml/min.
  • Gradient #3: Linear 900-0 mM (NH4)2SO4 over 4 CV, flow rate of 2.5 ml/min.
  • Gradient #4: Step gradient 1.5M-1.1M (NH4)2SO4 over 0.5 CV, followed by 1.1M-375 mM (NH4)2SO4 over 6 CV, and finally 375 mM-0 mM (NH4)2SO4 over 0.5 CV, flow rate of 2.5 ml/min.
  • Gradient #5: Linear 750-0 mM (NH4)2SO4 over 2 CV, flow rate of 2.5 ml/min.
  • Gradient #6: Step gradient 1.75M-0M (NH4)2SO4 over 6 CV, flow rate of 2.5 ml/min.
  • Gradient #7: Linear 750-0 mM (NH4)2SO4 over 6 CV, flow rate of 2.5 ml/min.
  • Example 1 Purification of HSA:First GLP-1 Analogue (SEQ ID NO:1) Conjugate
  • The first GLP-1 analogue is GLP-1 (7-36) dAla8 Lys37 (ε-AEEA-MPA)-CONH2 and has the following sequence:
  • H(dA)EGTFTSDVSSYLEGQAAKEFIAWLVKGRK(AEEA-MPA)-CONH2
  • The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GLP-1 analogue diluted into 9 ml of buffer made of 20 mM sodium phosphate buffer pH 7.0, 5 mM sodium caprylate and 750 mM (NH4)2SO4, was performed on a column of Butyl sepharose using the gradient #1 described above. In FIG. 1 the purified conjugate fraction elutes during the gradient of decreasing (NH4)2SO4 concentration as fraction B (F8-F9), whereas non-conjugated albumin elutes within the void volume of the column (fraction A). The conjugate fraction was concentrated with Ultrafree™ filter 30 kDa and analyzed using LC-EMS.
  • Example 2 Purification of HSA:First GRF Analogue (SEQ ID NO:2) Conjugate
  • The first GRF analogue is GRF (1-29) dAla2 Gln8 Ala15 Leu27 Lys30 (ε-MPA) CONH2 and has the following sequence:
  • YaDAIFTQSYRKVLAQLSARKLLQDILSRK(MPA)-CONH2
  • The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GRF analogue diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4, was performed on a column of Butyl sepharose using the gradient #1 described above. In FIG. 2 the purified conjugate fraction appears in fraction B (F6-F7) whereas non-conjugated albumin elutes within the void volume of the column (fraction A). The conjugate fraction was concentrated with Ultrafree™ filter 30 kDa and analyzed using LC-EMS.
  • Example 3 Purification of Non-Conjugated HSA 1 ml
  • The purification of 1 ml 25% 250 mg/ml non-conjugated HSA (Cortex-Biochem, San Leandro, Calif.) diluted into 9 ml of buffer (pH 7.0) made of 20 mM sodium phosphate buffer, 5 mM sodium caprylate and 750 mM (NH4)2SO4, was performed on a column of Butyl sepharose using the gradient #1 described above. Essentially all albumin molecules elute within the void volume and no protein species is observed at 280 nm during (NH4)2SO4 gradient. FIG. 3 illustrates the separation curve obtained.
  • Example 4 Purification of rHSA:First GLP-1 Analogue (SEQ ID NO:1) Conjugate
  • The first GLP-1 analogue is GLP-1 (7-36) dAla8 Lys37 (ε-AEEA-MPA)-CONH2 and his sequence is shown in Example 1.
  • The purification of a conjugate made from reacting 5 ml 5% rHSA (recombinant HSA new century culture grade) with 200 μM first GLP-1 analogue diluted into 5 ml of a buffer made of 20 mM sodium phosphate buffer, 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using the gradient #1 described above. In FIG. 4 the purified conjugate fraction appears in fraction B (F7-F8-F9).
  • Example 5 Purification of HSA 10 ml
  • The purification of 10 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) diluted into 40 ml of a buffer made of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using the gradient #1 described above. Essentially all albumin molecules elute within a void volume and no protein species is observed at 280 nm during (NH4)2SO4 gradient. FIG. 5 illustrates the separation curve obtained.
  • Example 6 Purification of HSA:K5 Analogue (SEQ ID NO:3) Conjugate
  • The K5 analogue is Ac-K5 Lys8 (ε-MPA)-NH2 and has the following sequence:
  • Figure US20080146783A1-20080619-C00001
  • The purification of a conjugate made from reacting 4 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM K5 analogue diluted into 16 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using the gradient #1 described above. In FIG. 6 the purified conjugate fraction appears in fraction A with albumin and in fraction B (F6-F7-F8).
  • Example 7 Purification of HSA:First Insulin Derivative (SEQ ID NO:4) Conjugate
  • The first insulin derivative is human insulin with MPA on position B1 and is represented in FIG. 1 below.
  • The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first insulin derivative diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using the gradient #1 described above. In FIG. 7 the purified conjugate fraction appears in fraction B (F6-F7-F8).
  • Example 8 Purification of HSA:Second Insulin Derivative (SEQ ID NO:5) Conjugate
  • The second insulin derivative is human insulin with MPA on position A1 and is represented in FIG. 1 shown above in Example 7.
  • The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM second insulin derivative diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 8 the purified conjugate fraction appears in fraction B (F6-F7-F8).
  • Example 9 Purification of HSA:First C34 Analogue (SEQ ID NO:6) Conjugate
  • The first C34 analogue is MPA-AEEA-C34-CONH2 and has the following sequence:
  • Figure US20080146783A1-20080619-C00002
  • The purification of a conjugate made from reacting 5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first C34 analogue diluted into 20 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 9 the purified conjugate fraction appears in fraction F2.
  • Example 10 Purification of HSA:Second C34 Analogue (SEQ ID NO:7) Conjugate
  • The second C34 analogue is C34 (1-34) Lys35 (ε-AEEA-MPA)-CONH2 and has the following structure:
  • Figure US20080146783A1-20080619-C00003
  • The purification of a conjugate made from reacting 5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM second C34 analogue diluted into 20 ml of 20 mM sodium phosphate buffer, 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 10 the purified conjugate fraction appears in fraction F2.
  • Example 11 Purification of HSA:Third C34 Analogue (SEQ ID NO:8) Conjugate
  • The third C34 analogue is C34 (1-34) Lys13 (ε-AEEA-MPA)-CONH2 and has the following structure:
  • Figure US20080146783A1-20080619-C00004
  • The purification of a conjugate made from reacting 5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM third C34 analogue diluted into 20 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4, was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 11 the purified conjugate fraction appears in fraction F2.
  • Example 12 Purification of l-Cysteine
  • The purification of 121 mg of 1-cysteine in 2 ml of a buffer made of 20 mM sodium phosphate, 5 mM sodium caprylate and 750 mM (NH4)2SO4, was performed on a column of Butyl sepharose using the gradient #5 described above. FIG. 12 illustrates the separation curve obtained, where L-cysteine elutes within the void volume of the column (F3).
  • Example 13 Purification of L-cysteine:First GLP-1 Analogue (SEQ ID NO:1) Conjugate
  • The first GLP-1 analogue is GLP-1 (7-36) dAla8 Lys37 (ε-AEEA-MPA)-CONH2 and his sequence is shown above in Example 1.
  • The purification of a conjugate made from reacting 121 mg L-cysteine with 36.36 mg first GLP-1 analogue diluted into 2 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #5 described above. FIG. 13 illustrates the separation curve obtained where the excess L-cysteine elutes in F3 (column void volume) and the L-Cysteine:first GLP-1 analogue conjugate elutes in 0 mM (NH4)2SO4.
  • Example 14 Purification of HSA:Second GLP-1 Analogue (SEQ ID NO:9) Conjugate
  • The second GLP-1 analogue is GLP-1 (7-36) Lys37 (ε-MPA)-NH2 and has the following sequence:
  • HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRK(ε-MPA)
  • The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM second GLP-1 analogue diluted into 10 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #5 described above. In FIG. 14 the purified conjugate fraction appears in fraction F2.
  • Example 15 Purification of HSA:Third GLP-1 Analogue (SEQ ID NO:10) Conjugate
  • The third GLP-1 analogue is GLP-1 (7-36) dAla8 Lys37 (ε-MPA)-NH2 and has the following sequence:
  • H(dA)EGTFTSDVSSYLEGQAAKEFIAWLVKGRK(MPA)-CONH2
  • The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM third GLP-1 analogue diluted into 10 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #5 described above. In FIG. 15 the purified conjugate fraction appears in fraction F2.
  • Example 16 Purification of HSA:Fourth GLP-1 Analogue (SEQ ID NO:11) Conjugate
  • The fourth GLP-1 analogue is GLP-1 (7-36) Lys26 (ε-AEEA-AEEA-MPA) and has the following sequence:
  • HAEGTFTSDVSSYLEGQMK(ε-AEEA-AEEA-MPA) EFIAWLVKGR
  • The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM fourth GLP-1 analogue diluted into 10 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 16 the purified conjugate fraction appears in fraction F2.
  • Example 17 Purification of HSA:Fifth GLP-1 Analogue (SEQ ID NO:12) Conjugate
  • The fifth GLP-1 analogue is GLP-1 (7-36) Lys34 (ε-AEEA-AEEA-MPA) and has the following sequence:
  • HAEGTFTSDVSSYLEGQAAKEFIAWLVK(ε-AEEA-AEEA-MPA)GR
  • The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM fifth GLP-1 analogue diluted into 10 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 17 the purified conjugate fraction appears in fraction F2.
  • Example 18 Purification of HSA:First Exendin-4 Analogue (SEQ ID NO:13) Conjugate
  • The first exendin-4 analogue is Exendin-4-(1-39) Lys40 (ε-MPA)-NH2 and has the following sequence:
  • HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK(ε-MPA)-
    CONH2
  • The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first Exendin-4 analogue diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 18 the purified conjugate fraction appears in fraction F2.
  • Example 19 Purification of HSA:Second Exendin-4 Analogue (SEQ ID NO:14) Conjugate
  • The second Exendin-4 analogue is Exendin-4 (9-39) Lys40 (ε-AEEA-MPA)-CONH2 and has the following sequence:
  • DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK(AEEA-MPA)-CONH2
  • The purification of a conjugate made from reacting 3.5 ml 25% HSA cortex with 1 mM second Exendin-4 analogue diluted into 21.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 19 the purified conjugate fraction appears in fraction F2.
  • Example 20 Purification of HSA:MPA
  • The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 2 mM MPA diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #2 described above. In FIG. 20 the fraction of mercaptalbumin is in fraction A (F5) and capped albumin is in fraction B (F7-F8). The conjugate fraction was concentrated with Amicon™ filter 30 kDa.
  • Example 21 Purification of HSA
  • The purification of 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using the gradient #2 described above. When using gradient #2, unlike gradients #1 and #5, both conjugated albumin and non-conjugated albumin adsorbs onto the hydrophobic resin during sample loading. FIG. 21 illustrates the separation curve obtained where F4 and F5 are enriched in mercaptalbumin and F6, F7 and F8 are enriched in capped albumin.
  • Example 22 Purification of HSA:Second C34 Analogue (SEQ ID NO:3) Conjugate
  • The second C34 analogue is C34 (1-34) Lys35 (ε-AEEA-MPA)-CONH2 and his structure is shown in Example 10.
  • The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM second C34 analogue diluted into 9 ml of a buffer made of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #2 described above. In FIG. 22 mercaptalbumin appears in fraction A (F5) and capped albumin and the purified conjugated is in fraction B (F7-F8).
  • Example 23 Purification of HSA:First Dynorphin A Analogue (SEQ ID NO:15) Conjugate
  • The first Dynorphin A analogue is Dyn A (1-13) (MPA)-NH2 and has the following sequence:
  • YGGFLRRIRPKLK(MPA)-CONH2.
  • The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first Dynorphin A analogue diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #2 described above. In FIG. 23 the purified conjugate fraction appears in fraction A (F11-F12)
  • Example 24 Purification of HSA:First ANP Analogue (SEQ ID NO:16) Conjugate
  • The first ANP analogue is MPA-AEEA-ANP (99-126)-CONH2 and has the following structure:
  • Figure US20080146783A1-20080619-C00005
  • The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first ANP analogue diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #2 described above. In FIG. 24 the purified conjugate fraction appears in fraction A (F14).
  • Example 25 Purification of HSA:Second Dynorphin A Analogue (SEQ ID NO:17) Conjugate
  • The second Dynorphin A analogue is Dyn A (7-13) Lys13 (ε-MPA)-CONH2 and has the following sequence:
  • RIRPKLK(MPA)-CONH2
  • The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM second Dynorphin A analogue diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #2 described above. In FIG. 25 the purified conjugate fraction appears in fraction A (F9).
  • Example 26 Purification of HSA:ACE Inhibitor (SEQ ID NO:18) Conjugate
  • The ACE inhibitor used in this example is acetyl-Phe-His-cyclohexylstatyl-Ile-Lys (ε-AEEA-MPA)-CONH2 and has the following sequence:
  • Figure US20080146783A1-20080619-C00006
  • The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM ACE inhibitor diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #2 described above. In FIG. 26 the purified conjugate fraction appears in fraction A (F14).
  • Example 27 Purification of HSA:Sixth GLP-1 Analogue (SEQ ID NO:19) Conjugate
  • The sixth GLP-1 analogue is GLP-1 (7-36) Lys23 (ε-AEEA-MPA)-CONH2 and has the following sequence:
  • HAEGTFTSDVSSYLEGK(AEEA-MPA)AAKEFIAWLVKGR-CONH2
  • The purification of a conjugate made from reacting 3 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM sixth GLP-1 analogue diluted into 22 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 27 the purified conjugate fraction appears in fraction F2.
  • Example 28 Purification of HSA:Seventh GLP-1 Analogue (SEQ ID NO:20) Conjugate
  • The seventh GLP-1 analogue is GLP-1 (7-36) Lys18 (ε-AEEA-MPA)-CONH2 and has the following sequence:
  • HAEGTFTSDVSK(AEEA-MPA)YLEGQAAKEFIAWLVKGR-CONH2
  • The purification of a conjugate made from reacting 3 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM seventh GLP-1 analogue diluted into 22 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 28 the purified conjugate fraction appears in fraction F2.
  • Example 29 Purification of HSA:Eighth GLP-1 Analogue (SEQ ID NO:21) Conjugate
  • The eighth GLP-1 analogue is GLP-1 (7-36) Lys26 (ε-AEEA-MPA)-CONH2 and has the following sequence:
  • HAEGTFTSDVSSYLEGQAAK(AEEA-MPA)EFIAWLVKGR-CONH2
  • The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM eighth GLP-1 analogue diluted into 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 29 the purified conjugate fraction appears in fraction F2.
  • Example 30 Purification of HSA:Ninth GLP-1 Analogue (SEQ ID NO:22) Conjugate
  • The ninth GLP-1 analogue is GLP-1 (7-37) Lys27 (ε-AEEA-MPA)-CONH2 and has the following sequence:
  • HAEGTFTSDVSSYLEGQAAKK(AEEA-MPA)FIAWLVKGR-CONH2
  • The purification of a conjugate made from reacting 3 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM ninth GLP-1 analogue diluted into 22 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 30 the purified conjugate fraction appears in fraction F2.
  • Example 31 Purification of HSA:Tenth GLP-1 Analogue (SEQ ID NO:23) Conjugate
  • The tenth GLP-1 analogue is GLP-1 (7-36) Lys37 (ε-AEEA-AEEA-MPA)-CONH2 and has the following sequence:
  • HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRK-AEEA-AEEA-MPA-
    CONH2
  • The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM tenth GLP-1 analogue diluted into 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 31 the purified conjugate fraction appears in fraction F2.
  • Example 32 Purification of HSA:Eleventh GLP-1 Analogue (SEQ ID NO:24) Conjugate
  • The eleventh GLP-1 analogue is GLP-1 (7-36) Lys37 (ε-AEEA-MPA)-CONH2 and has the following sequence:
  • HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRK(AEEA-MPA)-CONH2
  • The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM eleventh GLP-1 analogue diluted into 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 32 the purified conjugate fraction appears in fraction F2.
  • Example 33 Purification of HSA:Third Exendin-4 Analogue (SEQ ID NO:25) Conjugate
  • The third Exendin-4 analogue is Exendin-4-(1-39) Lys40 (ε-AEEA-MPA)-CONH2 and has the following sequence:
  • HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK(ε-AEEA-
    MPA)-CONH2
  • The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM third Exendin-4 analogue diluted into 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 33 the purified conjugate fraction appears in fraction F2.
  • Example 34 Purification of HSA:Twelfth GLP-1 Analogue (SEQ ID NO:26) Conjugate
  • The twelfth GLP-1 analogue is GLP-1 (7-36) Lys34 (ε-AEEA-MPA)-CONH2 and has the following sequence:
  • HAEGTFTSDVSSYLEGQAAKEFIAWLVK(ε-AEEA-MPA)GR-CONH2
  • The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM twelfth GLP-1 analogue diluted into 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 34 the purified conjugate fraction appears in fraction F2.
  • Example 35 Purification of HSA:First Insulin Derivative (SEQ ID NO:4) Conjugate
  • The first insulin derivative is human insulin with MPA on position B1 and his structure is detailed in Example 7.
  • The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first insulin derivative diluted into 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 35 the purified conjugate fraction appears in fraction F2.
  • Example 36 Purification of HSA:Third Insulin Derivative (SEQ ID NO:27) Conjugate
  • The third insulin derivative is human insulin with OA-MPA on position B1 and is represented in FIG. 1 shown above in Example 7.
  • The purification of a conjugate made from reacting 4 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM third insulin derivative diluted into 21 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 36 the purified conjugate fraction appears in fraction F2.
  • Example 37 Purification of HSA:Second Insulin Derivative (SEQ ID NO:5) Conjugate
  • The second insulin derivative is human insulin with MPA on position A1 and is represented in FIG. 1 shown above in Example 7.
  • The purification of a conjugate made from reacting 3 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM second insulin derivative diluted into 22 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 37 the purified conjugate fraction appears in fraction F2.
  • Example 38 Purification of HSA:Fourth Insulin Derivative (SEQ ID NO:28) Conjugate
  • The fourth insulin derivative is human insulin with MPA on position B29 and is represented in FIG. 1 shown above in Example 7.
  • The purification of a conjugate made from reacting 3 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM fourth insulin derivative diluted into 22 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 38 the purified conjugate fraction appears in fraction F2.
  • Example 39 Purification of HSA:First GRF Analogue (SEQ ID NO:2) Conjugate
  • The first GRF analogue is GRF (1-29) dAla2 Gln8 Ala15 Leu27 Lys30 (ε-MPA) CONH2 and his sequence is shown in Example 2.
  • The purification of a conjugate made from reacting 3.7 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GRF analogue diluted into 22 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 39 the purified conjugate fraction appears in fraction F2.
  • Example 40 Purification of HSA:Second GRF Analogue (SEQ ID NO:29) Conjugate
  • The second GRF analogue is GRF(1-29) Lys30 (ε-MPA)-CONH2 and has the following sequence:
  • YADAIFTNSYRKVLGQLSARKLLQDIMSRK(MPA)-CONH2
  • The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM second GRF analogue diluted into 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 900 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #3 described above. In FIG. 40 the purified conjugate fraction appears in fraction F2.
  • Example 41 Purification of HSA:Third GRF Analogue (SEQ ID NO:30) Conjugate
  • The third GRF analogue is GRF (1-29) dAla2 Gln8 dArg11 Ala15 Leu27 Lys30 (ε-MPA)-CONH2 and has the following sequence:
  • YaDAIFTQSYrKVLAQLSARKLLQDILSRK(MPA)-CONH2
  • The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM third GRF analogue diluted into 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #3 described above. In FIG. 41 the purified conjugate fraction appears in fraction F2.
  • Example 42 Purification of HSA:Fourth GRF Analogue (SEQ ID NO:31) Conjugate
  • The fourth GRF analogue is GRF (1-29) dAla2 Lys30 (ε-MPA)-CONH2 and has the following sequence:
  • YaDAIFTNSYRKVLGQLSARKLLQDIMSRK(MPA)-CONH2
  • The purification of a conjugate made from reacting 2.5 ml 25% HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM fourth GRF analogue diluted in 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 900 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #3 described above. In FIG. 42 the purified conjugate fraction appears in fraction F2.
  • Example 43 Purification of HSA:Thirteenth GLP-1 Analogue CJC 1365 (SEQ ID NO:32) Conjugate
  • The thirteenth GLP-1 analogue is GLP-1 (9-36) Lys37 (ε-AEEA-MPA)-CONH2 and has the following sequence:
  • EGTFTSDVSSYLEGQAAKEFIAWLVKGRK(ε-AEEA-MPA)-CONH2
  • The purification of a conjugate made from reacting 3.5 ml 25% HSA (Cortex-Biochem, San Leandro, Calif.) and 1 mM thirteenth GLP-1 analogue diluted in 21.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 43 the purified conjugate fraction appears in fraction F2.
  • Example 44 Purification of HSA Lactose:First GLP-1 Analogue (SEQ ID NO:1) Conjugate
  • The first GLP-1 analogue is GLP-1 (7-36) dAla8 Lys37 (ε-AEEA-MPA)-CONH2 and his sequence is shown above in Example 1.
  • The purification of a conjugate made from reacting 4 ml 25% lactosaminated albumin (HSA pre-incubated with excess lactose at 37° C., pH 7.0) with 200 μM first GLP-1 analogue in 4 ml of a buffer made of 20 mM sodium phosphate, 5 mM sodium caprylate and 750 mM (NH4)2SO4, (pH 7.0) was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 44 the purified lactosaminated conjugate fraction appears in fraction F2.
  • Example 45 Purification of HSA:First T20 Analogue (SEQ ID NO:33) Conjugate
  • The first T20 analogue is Ac-T20 (1-36) Lys37 (ε-AEEA-MPA)-CONH2 and ahs the following sequence:
  • Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFK(AEEA-
    MPA)-CONH2
  • The purification of a conjugate made from reacting 2.5 ml 25% HSA with 1 mM first T20 analogue in 10 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 45 the purified conjugate fraction appears in fraction F2.
  • Example 46 Purification of HSA:First T1249 Analogue (SEQ ID NO:34) Conjugate
  • The first T1249 analogue is Ac-T1249 (1-39) Lys40 (ε-AEEA-MPA)-CONH2 and has the following sequence:
  • Ac-WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWFK(AEEA-
    MPA)-CONH2
  • The purification of a conjugate made from reacting 2 ml 25% HSA and 1 mM first T1249 analogue in 10.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 46 the purified conjugate fraction appears in fraction F4.
  • Example 47 Purification of a HSA:First GLP-1 Analogue (SEQ ID NO:1)
  • The first GLP-1 analogue is GLP-1 (7-36) dAla8 Lys37 (ε-AEEA-MPA)-CONH2 and his sequence is shown in Example 1.
  • The purification of 114.45 mg of the preformed conjugate of the first GLP-1 analogue in 12.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #5 described above. FIG. 47 illustrates the separation curve obtained with the conjugate found in fraction F2.
  • Example 48 Purification of a HSA:First C34 Analogue (SEQ ID NO:6)
  • The first C34 analogue is MPA-AEEA-C34-CONH2 and his sequence is shown above in Example 9.
  • The purification of 114.45 mg of the preformed conjugate of the first C34 analogue in 12.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #5 described above. FIG. 48 illustrates the separation curve obtained with the conjugate found in fraction F2.
  • Example 49 Purification of a HSA:Second GRF Analogue (SEQ ID NO:29)
  • The second GRF analogue is GRF(1-29) Lys30 (ε-MPA)-CONH2 and his sequence is shown above in Example 40.
  • The purification of 125.53 mg of the preformed conjugate of the second GRF analogue in 12.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4, pH 7.0 was performed on a column of Butyl sepharose using gradient #5 described above. FIG. 49 illustrates the separation curve obtained with the conjugate found in fraction F2.
  • Example 50 Purification of HSA:Vinorelbine Analogue Conjugate (SEQ ID NO:35)
  • The vinorelbine analogue is a molecule of vinorelbine with AEEA-MPA coupled thereto as illustrated in the following structure:
  • Figure US20080146783A1-20080619-C00007
  • The purification of a conjugate made from 2.5 ml 25% HSA and 1 mM vinorelbine analogue in 22.5 ml of a buffer made of 20 mM sodium phosphate buffer, 5 mM sodium caprylate and 750 mM (NH4)2SO4, pH 7.0 was performed on a column of Butyl sepharose using gradient #4 described above. In FIG. 50 the purified conjugate fraction appears in fraction F2. The conjugate fraction was concentrated with Amicon™ filter 30 kDa.
  • Example 51 Purification of L-Cysteine
  • The purification of 2.5 ml 40 mM L-cysteine in 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1500 mM (NH4)2SO4, was performed on a column of Butyl sepharose using gradient #4 described above. FIG. 51 illustrates the separation curve obtained with L-cysteine eluting within the void volume of the column (fraction F3).
  • Example 52 Purification of L-Cysteine:Vinorelbine Analogue (SEQ ID NO:35) Conjugate
  • The vinorelbine analogue is a molecule of vinorelbine with AEEA-MPA coupled thereto as illustrated in the structure shown in Example 50.
  • The purification of a conjugate made from reacting 2.5 ml 40 mM L-cysteine with 1 mM vinorelbine analogue in 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #4 described above. FIG. 52 illustrates the separation curve obtained with the L-cysteine conjugate eluting within fractions F8, F9 and F10.
  • Example 53 Purification of RSA:Third Exendin-4 Analogue (SEQ ID NO:25) Conjugate
  • The third Exendin-4 analogue is Exendin-4-(1-39) Lys40 (ε-AEEA-MPA)-CONH2 and his sequence shown in Example 33.
  • The purification of a conjugate made from reacting 11 ml 5% RSA (rat serum albumin) with 200 μM third Exendin-4 analogue in 11 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4, was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 53 the purified conjugate fraction appears in fraction F2.
  • Example 54 Purification of HSA:Fourth C34 Analogue (SEQ ID NO:36) Conjugate
  • The fourth C34 analogue is C34 (1-34) Lys13 (ε-MPA)-CONH2 and has the following sequence:
  • WMEWDREINNYTK(MPA)LIHSLIEESQNQQEKNEQELL-CONH2
  • The purification of a conjugate made from reacting 2 ml 25% HSA with 1 mM fourth C34 analogue in 13 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 54 the purified conjugate fraction appears in fraction F2.
  • Example 55 Purification of HSA:Fifth C34 Analogue (SEQ ID NO:37) Conjugate
  • The fifth C34 analogue is C34 (1-34) Lys35 (ε-MPA)-CONH2 and has the following sequence:
  • WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLK(MPA)-CONH2
  • The purification of a conjugate made from 2 ml 25% HSA and 1 mM fifth C34 analogue in 13 ml of a buffer made of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4, was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 55 the purified conjugate fraction appears in fraction F2.
  • Example 56 Purification of HSA:Sixth C34 Analogue (SEQ ID NO:38) Conjugate
  • The sixth C34 analogue MPA-C34 (1-34)-CONH2 and has the following sequence:
  • MPA-WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL-CONH2
  • The purification of a conjugate made from reacting 2 ml 25% HSA and 1 mM sixth C34 analogue in 13 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 56 the purified conjugate fraction appears in fraction F2.
  • Example 57 Purification of HSA:Seventh C34 Analogue (SEQ ID NO:39) Conjugate
  • The seventh C34 analogue is Ac-C34 (1-34) Glu2 Lys6 Lys7 Glu9 Glu10 Lys13 Lys14 Glu16 Glu17 Lys20 Lys21 Glu23 Glu24 Lys27 Glu31 Lys34 Lys35 Lys36 (ε-AEEA-MPA)-CONH2 and has the following sequence:
  • Ac-WEEWOKKIEEYTKKIEELIKKSEEQQKKNEEELKKK(AEEA-MPA)-
    CONH2
  • The purification of a conjugate made from reacting 2 ml 25% HSA with 1 mM seventh C34 analogue in 13 ml 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4, was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 57 the purified conjugate fraction appears in fraction F2.
  • Example 58 Purification of HSA:Eighth C34 Analogue (SEQ ID NO:40) Conjugate
  • The eighth C34 analogue is MPA-AEEA-C34 (1-34) Glu2 Lys6 Lys7 Glu9 Glu10 Lys13 Lys14 Glu16 Glu17 Lys20 Lys21 Glu23 Glu24 Lys27 Glu31 Lys34 Lys35-CONH2 and has the following sequence:
  • MPA-AEEA-WEEWDKKIEEYTKKIEELIKKSEEQQKKNEEELKK-CONH2
  • The purification of a conjugate made from reacting 2 ml 25% HSA with 1 mM eighth C34 analogue in 13 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4, was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 58 the purified conjugate fraction appears in fraction F2.
  • Example 59 Purification of HSA:First PYY Analogue (SEQ ID NO:41) Conjugate
  • The first PYY analogue is PYY (3-36) Lys4 (ε-OA-MPA)-CONH2 and has the following structure:
  • Figure US20080146783A1-20080619-C00008
  • The purification of a conjugate made from reacting 1.5 ml 25% HSA with 1 mM first PYY analogue in 6 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4, was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 59 the purified conjugate fraction appears in fraction F2.
  • Example 60 Purification of HSA:Second PYY Analogue (SEQ ID NO:42) Conjugate
  • The second PYY analogue is MPA-OA-PYY (3-36)-CONH2 and has the following sequence:
  • Figure US20080146783A1-20080619-C00009
  • The purification of a conjugate made from reacting 1.5 ml 25% HSA with 1 mM second PYY analogue in 6 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4, was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 60 the purified conjugate fraction appears in fraction F2.
  • Example 61 Purification of HSA:Fifth Insulin Derivative (SEQ ID NO:43) Conjugate
  • The fifth insulin derivative is human insulin with AEEAS-AEEAS-MPA on position B29 and is represented in FIG. 1 shown above in Example 7.
  • The purification of a conjugate made from reacting 2 ml 25% HSA with 1 mM fifth insulin derivative in 15 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 61 the purified conjugate fraction appears in fraction F2.
  • Example 62 Purification of HSA:Sixth Insulin Derivative (SEQ ID NO:44) Conjugate
  • The sixth insulin derivative is human insulin with AEEAS-AEEAS-MPA on position B1 and is represented in FIG. 1 shown above in Example 7.
  • The purification of a conjugate made from reacting 2.5 ml 25% HSA with 1 mM sixth insulin derivative in 15 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 62 the purified conjugate fraction appears in fraction F2.
  • Example 63 Purification of HSA:Seventh Insulin Derivative (SEQ ID NO:45) Conjugate
  • The seventh insulin derivative is human insulin with OA-MPA on position B29 and is represented in FIG. 1 shown above in Example 7.
  • The purification of a conjugate made from reacting 2 ml 25% HSA with 1 mM seventh insulin derivative in 15 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 63 the purified conjugate fraction appears in fraction F2.
  • Example 64 Purification of HSA:Third PYY Analogue (SEQ ID NO:46) Conjugate
  • The third PYY analogue is MPA-PYY (3-36)-CONH2 and has the following sequence:
  • MPA-NH-IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-CONH2
  • The purification of a conjugate made from reacting 3 ml 25% HSA with 1 mM third PYY analogue in 18 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 64 the purified conjugate fraction appears in fraction F2.
  • Example 65 Purification of HSA:Fourth PYY Analogue (SEQ ID NO:47) Conjugate
  • The fourth PYY analogue is PYY (3-36) Lys37 (ε-MPA)-CONH2 and has the following sequence:
  • IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRYK(MPA)-CONH2
  • The purification of a conjugate made from reacting 3 ml 25% HSA with 1 mM fourth PYY analogue in 18 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #1 described above. In FIG. 65 the purified conjugate fraction appears in fraction F2.
  • Example 66 Purification of HSA:Fifth PYY Analogue (SEQ ID NO:48) Conjugate
  • The fifth PYY analogue is MPA-PYY (22-36)-CONH2 and has the following sequence: (MPA)-ASLRHYLNLVTRQRY-CONH2.
  • The purification of a conjugate made from reacting 6 ml 25% HSA with 1 mM fifth PYY analogue in 36 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 900 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #3 described above. In FIG. 66 the purified conjugate fraction appears in fraction F2.
  • Example 67 Purification of HSA:Sixth PYY Analogue (SEQ ID NO:49) Conjugate
  • The sixth PYY analogue is Acetyl-PYY (22-36) Lys37 (ε-MPA)-CONH2 and has the following sequence: Ac-ASLRHYLNLVTRQRYK(MPA)-CONH2.
  • The purification of a conjugate made from reacting 6 ml 25% HSA with 1 mM sixth PYY analogue in 36 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 900 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #3 described above. In FIG. 67 the purified conjugate fraction appears in fraction F2.
  • Example 68 Purification of HSA:Second ANP Analogue (SEQ ID NO:50) Conjugate
  • The second ANP analogue is MPA-ANP (99-126)-CONH2 and has the following structure:
  • Figure US20080146783A1-20080619-C00010
  • The purification of a conjugate made from reacting 1 ml 25% HSA with 1 mM second ANP analogue in 14 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #3 described above. In FIG. 68 the purified conjugate fraction appears in fraction F2.
  • Example 69 Purification of HSA:Third ANP Analogue (SEQ ID NO:51) Conjugate
  • The third ANP analogue is ANP (99-126) having reacted with MAL-dPEG4™ (Quanta Biodesign, Powell, Ohio, USA) coupled to Ser99. The resulting ANP analogue is MPA-EEEEP-ANP (99-126) where EEEEP is ethoxy ethoxy ethoxy ethoxy propionic acid; and its sequence is the following:
  • Figure US20080146783A1-20080619-C00011
  • The purification of a conjugate made from reacting 1 ml 25% HSA with 1 mM CJC 1681 in 14 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 900 mM (NH4)2SO4 was performed on a column of Butyl sepharose using gradient #3 described above. In FIGS. 69A and 69B the purified conjugate fraction appears in fraction F2.
  • Example 70 Purification of HSA:First GLP-1 Analogue (SEQ ID NO:1) Conjugate
  • The first GLP-1 analogue is GLP-1 (7-36) dAla8 Lys37 (ε-AEEA-MPA)-CONH2 and his sequence is shown above in Example 1.
  • The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GLP-1 analogue diluted into 9 ml of buffer made of 20 mM sodium phosphate buffer pH 7.0, 5 mM sodium caprylate and 1.75M (NH4)2SO4, was performed on a column of Butyl sepharose using the gradient #6 described above. In FIG. 70 the purified conjugate fraction appears in fraction B.
  • Example 71 Purification of HSA:First GLP-1 Analogue (SEQ ID NO:1) Conjugate
  • The first GLP-1 analogue is GLP-1 (7-36) dAla8 Lys37 (ε-AEEA-MPA)-CONH2 and his sequence is shown above in Example 1.
  • The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GLP-1 analogue diluted into 9 ml of buffer made of 20 mM sodium phosphate buffer pH 7.0, 5 mM sodium caprylate and 1.75M magnesium sulfate, was performed on a column of Butyl sepharose using the gradient #6 described above. In FIG. 71 the purified conjugate fraction appears in fraction F2.
  • Example 72 Purification of HSA:First GLP-1 Analogue (SEQ ID NO:1) Conjugate
  • The first GLP-1 analogue is GLP-1 (7-36) dAla8 Lys37 (ε-AEEA-MPA)-CONH2 and his sequence is shown above in Example 1.
  • Example with 750 mM ammonium sulfate The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GLP-1 analogue diluted into 9 ml of buffer made of 20 mM sodium phosphate buffer pH 7.0, 5 mM sodium caprylate and 750 mM (NH4)2SO4, was performed on a column of Butyl sepharose using the gradient #1 described above. In FIG. 72 the purified conjugate fraction appears in fraction F2.
  • Example 73 Purification of HSA:First GLP-1 Analogue (SEQ ID NO:1) Conjugate
  • The first GLP-1 analogue is GLP-1 (7-36) dAla8 Lys37 (ε-AEEA-MPA)-CONH2 and his sequence is shown above in Example 1.
  • Example with 1.75M ammonium phosphate The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GLP-1 analogue diluted into 9 ml of buffer made of 20 mM sodium phosphate buffer pH 7.0, 5 mM sodium caprylate and 1.75M ammonium phosphate, was performed on a column of Butyl sepharose using the gradient #6 described above. In FIG. 73 the purified conjugate fraction appears in fraction B.
  • Example 74 Purification of HSA:First GLP-1 Analogue (SEQ ID NO:1) Conjugate
  • The first GLP-1 analogue is GLP-1 (7-36) dAla8 Lys37 (ε-AEEA-MPA)-CONH2 and his sequence is shown above in Example 1.
  • Example with 750 mM ammonium phosphate The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GLP-1 analogue diluted into 9 ml of buffer made of 20 mM sodium phosphate buffer pH 7.0, 5 mM sodium caprylate and 750 mM ammonium phosphate, was performed on a column of Butyl sepharose using the gradient #1 described above. In FIG. 74 the purified conjugate fraction appears in fraction F2.
  • Example 75 Purification of HSA:First GLP-2 Analogue (SEQ ID NO:52) Conjugate
  • The first GLP-2 analogue is GLP-2 (1-33) Gly2 Lys34 (ε-MPA)-CONH2 and has the following sequence:
  • HGDGSFSDEMNTILDNLAARDFINWLIQTKITDK(MPA)-CONH2
  • The purification of a conjugate made from reacting 2 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GLP-2 analogue diluted into 14 ml of buffer made of 20 mM sodium phosphate buffer pH 7.0, 5 mM sodium caprylate and 750 mM (NH4)2SO4, was performed on a column of Butyl sepharose using the gradient #1 described above. In FIG. 75 the purified conjugate fraction appears in fraction F2.
  • Example 76 Purification of RSA:First GLP-2 Analogue (SEQ ID NO:52) Conjugate
  • The first GLP-2 analogue is GLP-2 (1-33) Gly2 Lys34 (ε-MPA)-CONH2 and his sequence is shown in Example 75.
  • The purification of a conjugate made from reacting 9 ml 25% 250 mg/ml RSA (rat serum albumin) with 1 mM first GLP-2 analogue diluted into 14 ml of buffer made of 20 mM sodium phosphate buffer pH 7.0, 5 mM sodium caprylate and 750 mM (NH4)2SO4, was performed on a column of Butyl sepharose using the gradient #1 described above. In FIG. 76 the purified conjugate fraction appears in fraction F2.
  • While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

Claims (26)

1-22. (canceled)
23. A method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin, the method comprising: contacting said solution with a hydrophobic interaction chromatography matrix under conditions wherein the albumin conjugate binds to said matrix and the unconjugated albumin does not bind to said matrix, wherein the albumin conjugate comprises a peptide.
24. The method of claim 23, wherein said hydrophobic interaction chromatography matrix is a column containing a hydrophobic resin.
25. The method of claim 24, wherein said hydrophobic resin is a bead-formed agarose-based gel filtration matrix covalently coupled to a ligand selected from the group consisting of an octyl group, a phenyl group and a butyl group.
26. The method of claim 25, wherein said hydrophobic resin is a bead-formed agarose-based gel filtration matrix covalently coupled to a butyl group.
27. The method of claim 23, wherein the hydrophobic interaction chromatography matrix is, prior to contact with said solution, equilibrated in aqueous buffer at a salt concentration high enough to promote matrix-protein interactions.
28. The method of claim 27, wherein the said salt concentration is between 500 and 3000 mM.
29. The method of claim 27, wherein said salt is selected from the group consisting of ammonium phosphate, ammonium sulfate, magnesium phosphate.
30. The method of claim 27, wherein said salt is ammonium sulfate.
31. The method of claim 27, wherein the pH of said aqueous buffer is between 3.0 and 9.0.
32. The method of claim 27, wherein the pH of said aqueous buffer is 7.0.
33. The method of claim 27, wherein said aqueous buffer and said hydrophobic interaction chromatography matrix are at a temperature of between 4° C. and about 25° C.
34. The method of claim 27, further comprising applying a gradient of decreasing salt concentration to said hydrophobic interaction chromatography matrix following contact with said solution.
35. The method of claim 34, further comprising collecting the eluted albumin conjugate.
36. The method of claim 23, wherein said albumin conjugate consists of a peptide comprising a Michael acceptor covalently bonded to albumin.
37. The method of claim 36, wherein said bond is between said Michael acceptor and cysteine 34 of said albumin.
38. The method of claim 37, wherein said Michael acceptor is maleimide-propionic acid.
39. The method of claim 36, wherein said peptide is covalently bonded to said Michael acceptor, optionally through a linker.
40. The method of claim 39, wherein said peptide is covalently bonded to said Michael acceptor through a linker selected from the group consisting of (2-amino)ethoxy acetic acid (AEA), ethylenediamine (EDA), 2-[2-(2-amino)ethoxy]ethoxy acetic acid (AEEA), amino ethoxy ethyl amino succinic acid (AEEAS), glycine, 3-aminopropionic acid (APA), 8-aminooctanoic acid (AOA), octanoic acid (OA), and 4-aminobenzoic acid (APhA).
41. The method of claim 39, wherein said peptide is selected from the group consisting of glucagon like peptide 1 (GLP-1), glucagon like peptide 2 (GLP-2), atrial natriuretic peptide (ANP), kringle 5 (K5), dynorphin, exendin-4, growth hormone releasing factor (GRF), insulin, natriuretic peptides, enfuvirtide (T-20), T-1249, C-34, soluble C-35 peptide EK (SC-35), peptide YY (PYY), and analogs thereof.
42. The method of claim 39, wherein said peptide is GLP-1 (7-36) dAla8 Lys37-CONH2.
43. The method of claim 39, wherein said peptide is Exendin-4 (1-39) Lys40-CONH2.
44. The method of claim 36, wherein said peptide comprising a Michael acceptor is selected from the group consisting of GLP-1 (7-36) dAla8 Lys37 (ε-AEEA-MPA)-CONH2 (SEQ ID NO:1), GRF (1-29) dAla2 Gln8 Ala15 Leu27 Lys30 (ε-MPA) CONH2 (SEQ ID NO:2), Ac-K5 Lys8 (ε-MPA)-NH2 (SEQ ID NO:3), Insulin B1-MPA (SEQ ID NO:4), Insulin A1-MPA (SEQ ID NO:5), MPA-AEEA-C34-CONH2 (SEQ ID NO:6), C34 (1-34) Lys35 (ε-AEEA-MPA)-CONH2 (SEQ ID NO:7), C34 (1-34) Lys13 (ε-AEEA-MPA)-CONH2 (SEQ ID NO:8), GLP-1 (7-36) Lys37 (ε-MPA)-NH2 (SEQ ID NO:9), GLP-1 (7-36) dAla8 Lys37 (ε-MPA)-NH2 (SEQ ID NO:10), GLP-1 (7-36) Lys26 (ε-AEEA-AEEA-MPA) (SEQ ID NO:11), GLP-1 (7-36) Lys34 (ε-AEEA-AEEA-MPA) (SEQ ID NO:12), Exendin-4-(1-39) Lys40 (ε-MPA)-NH2 (SEQ ID NO:13), Exendin-4 (9-39) Lys40 (ε-AEEA-MPA)-CONH2 (SEQ ID NO:14), Dyn A (1-13) (MPA)-NH2 (SEQ ID NO:15), MPA-AEEA-ANP (99-126)-CONH2 (SEQ ID NO:16), Dyn A (7-13) Lys13 (ε-MPA)-CONH2 (SEQ ID NO:17), acetyl-Phe-His-cyclohexylstatyl-Ile-Lys (ε-AEEA-MPA)-CONH2 (SEQ ID NO:18), GLP-1 (7-36) Lys23 (ε-AEEA-MPA)-CONH2 (SEQ ID NO:19), GLP-1 (7-36) Lys18 (ε-AEEA-MPA)-CONH2 (SEQ ID NO:20), GLP-1 (7-36) Lys26 (ε-AEEA-MPA)-CONH2 (SEQ ID NO:21), GLP-1 (7-37) Lys7 (ε-AEEA-MPA)-CONH2 (SEQ ID NO:22), GLP-1 (7-36) Lys37 (ε-AEEA-AEEA-MPA)-CONH2 (SEQ ID NO:23), GLP-1 (7-36) Lys37 (ε-AEEA-MPA)-CONH2 (SEQ ID NO:24), Exendin-4-(1-39) Lys40 (ε-AEEA-MPA)-CONH2 (SEQ ID NO:25), GLP-1 (7-36) Lys34 (ε-AEEA-MPA)-CONH2 (SEQ ID NO:26), Insulin B1-OA-MPA (SEQ ID NO:27), Insulin B29-MPA (SEQ ID NO:28), GRF (1-29) Lys30 (ε-MPA)-CONH2 (SEQ ID NO:29), GRF (1-29) dAla2 Gln8 dArg11 Ala15 Leu27 Lys30 (ε-MPA)-CONH2 (SEQ ID NO:30), GRF (1-29) dAla2 Lys30 (ε-MPA)-CONH2 (SEQ ID NO:31), GLP-1 (9-36) Lys37 (ε-AEEA-MPA)-CONH2 (SEQ ID NO:32), Ac-T20 (1-36) Lys37 (ε-AEEA-MPA)-CONH2 (SEQ ID NO:33), Ac-T1249 (1-39) Lys40 (ε-AEEA-MPA)-CONH2 (SEQ ID NO:34), 3′,4′-didehydro-4′-deoxy-C′-norvincaleukoblastine-AEEA-MPA, C34 (1-34) Lys13 (ε-MPA)-CONH2 (SEQ ID NO:36), C34 (1-34) Lys35 (ε-MPA)-CONH2 (SEQ ID NO:37), MPA-C34 (1-34)-CONH2 (SEQ ID NO:38), Ac-C34 (1-34) Glu2 Lys6 Lys7 Glu9 Glu10 Lys13 Lys14 Glu16 Glu17 Lys20 Lys21 Glu23 Glu24 Lys27 Glu31 Lys34 Lys35 Lys36 (ε-AEEA-MPA)-CONH2 (SEQ ID NO:39), MPA-AEEA-C34 (1-34) Glu2 Lys6 Lys7 Glu9 Glu10 Lys13 Lys14 Glu16 Glu17 Lys20 Lys21 Glu23 Glu24 Lys27 Glu31 Lys34 Lys35 CONH2 (SEQ ID NO:40), PYY (3-36) Lys4 (ε-OA-MPA)-CONH2 (SEQ ID NO:41), MPA-OA-PYY (3-36)-CONH2 (SEQ ID NO:42), Insulin B29-AEES2-MPA (SEQ ID NO:43), Insulin B1-AEES2-MPA (SEQ ID NO:44), Insulin B29-OA-MPA (SEQ ID NO:45), MPA-PYY (3-36)-CONH2 (SEQ ID NO:46), PYY (3-36) Lys37 (ε-MPA)-CONH2 (SEQ ID NO:47), MPA-PYY (22-36)-CONH2 (SEQ ID NO:48), Acetyl-PYY (22-36) Lys37 (ε-MPA)-CONH2 (SEQ ID NO:49), MPA-ANP (99-126)-CONH2 (SEQ ID NO:50), MPA-EEEEP-ANP (99-126) (SEQ ID NO:51), and GLP-2 (1-33) Gly2 Lys34 (ε-MPA)-CONH2 (SEQ ID NO:52).
45. The method of claim 23, wherein said albumin is selected from the group consisting of serum albumin and recombinant albumin.
46. The method of claim 23, wherein said albumin is human serum albumin.
47. A hydrophobic interaction chromatography matrix to which an albumin conjugate is bound, wherein said albumin conjugate comprises a peptide.
US11/981,474 2004-04-23 2007-10-30 Method for the purification of albumin conjugates Abandoned US20080146783A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US56522804P true 2004-04-23 2004-04-23
US11/112,277 US7307148B2 (en) 2004-04-23 2005-04-22 Method for purification of albumin conjugates
US11/981,474 US20080146783A1 (en) 2004-04-23 2007-10-30 Method for the purification of albumin conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/981,474 US20080146783A1 (en) 2004-04-23 2007-10-30 Method for the purification of albumin conjugates
US12/885,036 US20120022234A1 (en) 2004-04-23 2010-09-17 Method for the purification of albumin conjugates

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/112,277 Continuation US7307148B2 (en) 2004-04-23 2005-04-22 Method for purification of albumin conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/885,036 Continuation US20120022234A1 (en) 2004-04-23 2010-09-17 Method for the purification of albumin conjugates

Publications (1)

Publication Number Publication Date
US20080146783A1 true US20080146783A1 (en) 2008-06-19

Family

ID=35196920

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/112,277 Expired - Fee Related US7307148B2 (en) 2004-04-23 2005-04-22 Method for purification of albumin conjugates
US11/981,474 Abandoned US20080146783A1 (en) 2004-04-23 2007-10-30 Method for the purification of albumin conjugates
US12/885,036 Abandoned US20120022234A1 (en) 2004-04-23 2010-09-17 Method for the purification of albumin conjugates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/112,277 Expired - Fee Related US7307148B2 (en) 2004-04-23 2005-04-22 Method for purification of albumin conjugates

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/885,036 Abandoned US20120022234A1 (en) 2004-04-23 2010-09-17 Method for the purification of albumin conjugates

Country Status (24)

Country Link
US (3) US7307148B2 (en)
EP (3) EP2230257A1 (en)
JP (1) JP2007535507A (en)
CN (1) CN1956998B (en)
AT (2) AT433999T (en)
AU (1) AU2005235634B2 (en)
BR (1) BRPI0510117A (en)
CA (1) CA2564031A1 (en)
DE (2) DE602005022239D1 (en)
DK (2) DK1745078T3 (en)
EA (1) EA011168B1 (en)
ES (2) ES2328591T3 (en)
HK (2) HK1096102A1 (en)
HR (1) HRP20060362A2 (en)
IL (1) IL178369D0 (en)
MA (1) MA28587B1 (en)
MX (1) MXPA06012260A (en)
NO (1) NO20065037L (en)
PT (2) PT1745078E (en)
RS (1) RS20060578A (en)
SI (1) SI1745078T1 (en)
TN (1) TNSN06340A1 (en)
WO (1) WO2005103087A1 (en)
ZA (1) ZA200608475B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070269863A1 (en) * 2005-12-22 2007-11-22 Bridon Dominique P Process for the production of preformed conjugates of albumin and a therapeutic agent

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
PT1264840E (en) * 1999-05-17 2010-01-04 Conjuchem Biotechnologies Inc Long lasting fusion peptide inhibitors of viral infection
CA2501421A1 (en) * 1999-05-17 2000-11-23 Conjuchem Inc. Long lasting exendin-4
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
PT1360202E (en) * 2001-02-16 2008-09-01 Conjuchem Biotechnologies Inc Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
PT1479691E (en) * 2001-05-31 2007-02-28 John Erickson Long lasting fusion peptide inhibitors for hiv infection
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US20080039532A1 (en) * 2004-05-06 2008-02-14 Dominique Bridon Compounds For Specific Viral Target
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
EP2114437A2 (en) * 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
EP2147016A2 (en) * 2007-05-16 2010-01-27 ConjuChem Biotechnologies Inc. Cysteic acid derivatives of anti-viral peptides
US20090054332A1 (en) * 2007-06-21 2009-02-26 Conjuchem Biotechnologies, Inc. Thombopoietin peptide conjugates
CA2708762A1 (en) * 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
EP2247298B1 (en) * 2007-12-31 2016-08-31 New York University Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
ES2563553T3 (en) 2008-04-01 2016-03-15 Novo Nordisk A/S Insulin-albumin conjugates
CN101987868B (en) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Derivative or pharmaceutically acceptable salt of GLP-1 analogue and application of derivative or pharmaceutically-acceptable salt of a GLP-1 analogue
JP5892940B2 (en) 2009-11-25 2016-03-23 アリスジェン ソシエテ アノニム Crown compounds and / or counterion mucosal delivery compositions containing complexed peptide
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
AU2015205574A1 (en) * 2014-01-10 2016-07-07 Synthon Biopharmaceuticals B.V. Method for purifying Cys-linked antibody-drug conjugates
JP2017508139A (en) * 2014-01-31 2017-03-23 イクセラ,インコーポレイテッド Metabolites covalently bonded as a biomarker
US9616109B2 (en) * 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
CN105111306A (en) * 2015-08-28 2015-12-02 北京工业大学 Separation method of American alligator albumin
WO2017165607A1 (en) 2016-03-24 2017-09-28 The Administrators Of The Tulane Educational Fund Conjugates of tacrolimus, their compositions, and their uses

Citations (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206199A (en) * 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
US4251631A (en) * 1978-02-23 1981-02-17 Research Products Rehovot Ltd. Cross-linked enzyme membrane
US4462941A (en) * 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4678671A (en) * 1981-12-15 1987-07-07 Cordis Europa N.V. Conjugates of anticoagulant and protein
US4745100A (en) * 1985-05-14 1988-05-17 Eye Research Institute Of Retina Foundation Stimulation of tear secretion
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4859604A (en) * 1987-08-27 1989-08-22 Ampor, Inc. Composition for stabilization of diagnostic reagents
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5103233A (en) * 1991-04-16 1992-04-07 General Electric Co. Radar system with elevation-responsive PRF control, beam multiplex control, and pulse integration control responsive to azimuth angle
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5493007A (en) * 1991-04-05 1996-02-20 Genentech, Inc. Platelet aggregation inhibitors having high specificity for GPIIBIIIA
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5612458A (en) * 1993-12-23 1997-03-18 Dako/As Antibody to PNA/nucleic acid complexes
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5725804A (en) * 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US5770570A (en) * 1994-04-07 1998-06-23 Paul; Sudhir Method of delivering a vasoactive intestinal polypeptide, an encapsulated vasoactive intestinal polypeptide, and a method of making the encapsulated vasoactive intestinal polypeptide
US5807827A (en) * 1992-06-12 1998-09-15 Des-Tyr Dynorphin Partnership Des-Tyr dynorphin analogues
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5855866A (en) * 1992-03-05 1999-01-05 Board Of Regenis, The University Of Texas System Methods for treating the vasculature of solid tumors
US5869602A (en) * 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5874408A (en) * 1996-07-12 1999-02-23 Bayer Corporation Stabilized albumin-free recombinant factor VII preparation having a low sugar content
US5939390A (en) * 1995-03-09 1999-08-17 Novo Nordisk A/S Pharmaceutical composition
US5962649A (en) * 1994-08-31 1999-10-05 Yoshitomo Pharmaceutical Industries, Ltd. Process for purifying recombinant human serum albumin
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
US6191102B1 (en) * 1996-11-05 2001-02-20 Eli Lilly And Company Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6277583B1 (en) * 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
US20010018421A1 (en) * 1997-11-07 2001-08-30 Ezrin Alan M. Conjugate comprising an antinociceptive agent covalently bonded to a blood component
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US20020003999A1 (en) * 2000-03-09 2002-01-10 Claus Bonde Discharge and stacker device
US20020049153A1 (en) * 1999-05-17 2002-04-25 BRIDON Dominique P. Long lasting insulinoptropic peptides
US6403324B1 (en) * 1996-09-16 2002-06-11 Conjuchem, Inc. Affinity labeling libraries with tagged leaving group
US6440417B1 (en) * 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US20030073630A1 (en) * 2001-02-02 2003-04-17 BRIDON Dominique P. Long lasting growth hormone releasing factor derivatives
US20030170250A1 (en) * 1998-03-23 2003-09-11 Ezrin Alan M. Local delivery of long lasting therapeutic agents
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6706689B2 (en) * 2000-05-19 2004-03-16 Amylin Pharmaceuticals, Inc. Treatment of acute coronary syndrome with GLP-1
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US6723530B1 (en) * 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US6767887B1 (en) * 1996-06-05 2004-07-27 Roche Diagnostics Gmbh Exendin analogues, processes for their preparation and medicaments containing them
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20050037974A1 (en) * 1997-11-07 2005-02-17 Conjuchem, Inc. Affinity markers for human serum albumin
US6858576B1 (en) * 1996-08-08 2005-02-22 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6861236B2 (en) * 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
US20050065075A1 (en) * 2001-05-31 2005-03-24 Erickson John W. Long lasting fusion peptide inhibitors for hiv infection
US6872700B1 (en) * 1999-01-14 2005-03-29 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression
US20050070475A1 (en) * 1999-05-17 2005-03-31 Conjuchem, Inc. Long lasting fusion peptide inhibitors of viral infection
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6894024B2 (en) * 2000-10-20 2005-05-17 Amylin Pharmaceuticals, Inc. Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
US6902744B1 (en) * 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
US6905688B2 (en) * 2000-04-12 2005-06-14 Human Genome Sciences, Inc. Albumin fusion proteins
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US20050176643A1 (en) * 1999-05-17 2005-08-11 Conjuchem, Inc. Anti-obesity agents
US6956026B2 (en) * 1997-01-07 2005-10-18 Amylin Pharmaceuticals, Inc. Use of exendins for the reduction of food intake
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US6998387B1 (en) * 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US20060069029A1 (en) * 1999-01-14 2006-03-30 Kolterman Orville G Exendin analog formulations
US7041798B1 (en) * 1999-07-14 2006-05-09 Biotest Pharma Gmbh Method for the chromatographic fractionation of plasma or serum, preparations, so obtained, and their use
US7090851B1 (en) * 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
US7105508B1 (en) * 1999-08-09 2006-09-12 Abbott Gmbh & Co. Kg Integrin receptors antagonists
US7112567B2 (en) * 2001-02-16 2006-09-26 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
US20060233707A1 (en) * 1999-06-09 2006-10-19 Felix Kratz Process for producing an injectable medicament preparation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423034A (en) 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US20020018751A1 (en) 1993-10-15 2002-02-14 BRIDON Dominique P. Cellular and serum protein anchors for diagnostic imaging
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
JP2001504105A (en) 1996-11-12 2001-03-27 ノボ ノルディスク アクティーゼルスカブ Use of Glp-1 peptide
CN1268639C (en) * 1996-11-15 2006-08-09 基因技术股份有限公司 Purification of neurotrophins
US5981488A (en) 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
DE69812727D1 (en) 1997-11-07 2003-04-30 Conjuchem Inc Opioid conjugate with endogenous carrier proteins
JP2003522099A (en) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ Of glp-1 with delayed action profile glp-1 derivatives and exendin
ES2291210T3 (en) 1999-06-21 2008-03-01 Eli Lilly And Company thiazolidinediones synergistic with glucagon peptide-1 type and its agonists for treating insulin-dependent diabetes not.
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
EP1390061A2 (en) 2000-12-13 2004-02-25 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
SE526227C2 (en) * 2002-05-15 2005-08-02 North China Pharmaceutical Group Method for purifying recombinant human serum albumin
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
CA2550050A1 (en) * 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents

Patent Citations (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206199A (en) * 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
US4251631A (en) * 1978-02-23 1981-02-17 Research Products Rehovot Ltd. Cross-linked enzyme membrane
US4678671A (en) * 1981-12-15 1987-07-07 Cordis Europa N.V. Conjugates of anticoagulant and protein
US4462941A (en) * 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4745100A (en) * 1985-05-14 1988-05-17 Eye Research Institute Of Retina Foundation Stimulation of tear secretion
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5958909A (en) * 1986-05-05 1999-09-28 The General Hospital Corporation Insulinotropic hormones and uses thereof
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4859604A (en) * 1987-08-27 1989-08-22 Ampor, Inc. Composition for stabilization of diagnostic reagents
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US6103233A (en) * 1990-10-03 2000-08-15 Conjuchem, Inc. Cellular and serum protein anchors and conjugates
US5725804A (en) * 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US5493007A (en) * 1991-04-05 1996-02-20 Genentech, Inc. Platelet aggregation inhibitors having high specificity for GPIIBIIIA
US5103233A (en) * 1991-04-16 1992-04-07 General Electric Co. Radar system with elevation-responsive PRF control, beam multiplex control, and pulse integration control responsive to azimuth angle
US5855866A (en) * 1992-03-05 1999-01-05 Board Of Regenis, The University Of Texas System Methods for treating the vasculature of solid tumors
US5807827A (en) * 1992-06-12 1998-09-15 Des-Tyr Dynorphin Partnership Des-Tyr dynorphin analogues
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US20020009441A1 (en) * 1993-10-15 2002-01-24 Philippe Pouletty Reactively modified therapeutic compounds having an extended lifetime in vivo
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US6133235A (en) * 1993-12-09 2000-10-17 Eli Lilly And Company Glucagon-like insulinotropic peptides compositions and methods
US5612458A (en) * 1993-12-23 1997-03-18 Dako/As Antibody to PNA/nucleic acid complexes
US5770570A (en) * 1994-04-07 1998-06-23 Paul; Sudhir Method of delivering a vasoactive intestinal polypeptide, an encapsulated vasoactive intestinal polypeptide, and a method of making the encapsulated vasoactive intestinal polypeptide
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5962649A (en) * 1994-08-31 1999-10-05 Yoshitomo Pharmaceutical Industries, Ltd. Process for purifying recombinant human serum albumin
US5939390A (en) * 1995-03-09 1999-08-17 Novo Nordisk A/S Pharmaceutical composition
US5869602A (en) * 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US6277583B1 (en) * 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
US6767887B1 (en) * 1996-06-05 2004-07-27 Roche Diagnostics Gmbh Exendin analogues, processes for their preparation and medicaments containing them
US6087375A (en) * 1996-07-01 2000-07-11 Conjuchem, Inc. Methods of treating or preventing thromboses
US5942620A (en) * 1996-07-01 1999-08-24 Conjuchem, Inc. Methods for producing novel conjugates of thrombin inhibitors
US6277863B1 (en) * 1996-07-01 2001-08-21 Conjuchem, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5874408A (en) * 1996-07-12 1999-02-23 Bayer Corporation Stabilized albumin-free recombinant factor VII preparation having a low sugar content
US6858576B1 (en) * 1996-08-08 2005-02-22 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6403324B1 (en) * 1996-09-16 2002-06-11 Conjuchem, Inc. Affinity labeling libraries with tagged leaving group
US6583111B1 (en) * 1996-11-05 2003-06-24 Eli Lilly And Company Use of GLP-1 analogs and derivative adminstered peripherally in regulation of obesity
US6191102B1 (en) * 1996-11-05 2001-02-20 Eli Lilly And Company Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
US6956026B2 (en) * 1997-01-07 2005-10-18 Amylin Pharmaceuticals, Inc. Use of exendins for the reduction of food intake
US6989366B2 (en) * 1997-01-07 2006-01-24 Amylin Pharmaceuticals, Inc. Exendins, exendin agonists, and methods for their use
US6723530B1 (en) * 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US20050037974A1 (en) * 1997-11-07 2005-02-17 Conjuchem, Inc. Affinity markers for human serum albumin
US7166695B2 (en) * 1997-11-07 2007-01-23 Conjuchem Biotechnologies Inc. Affinity markers for human serum albumin
US20010018421A1 (en) * 1997-11-07 2001-08-30 Ezrin Alan M. Conjugate comprising an antinociceptive agent covalently bonded to a blood component
US6610825B2 (en) * 1997-11-07 2003-08-26 Conjuchem, Inc. Method for alleviating pain or providing an analgesic effect in a patient
US6602981B2 (en) * 1997-11-07 2003-08-05 Conjuchem, Inc. Antinociceptive agent derivative
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
US6998387B1 (en) * 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US20030170250A1 (en) * 1998-03-23 2003-09-11 Ezrin Alan M. Local delivery of long lasting therapeutic agents
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6440417B1 (en) * 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6437092B1 (en) * 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
US6872700B1 (en) * 1999-01-14 2005-03-29 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression
US20060069029A1 (en) * 1999-01-14 2006-03-30 Kolterman Orville G Exendin analog formulations
US6902744B1 (en) * 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6593295B2 (en) * 1999-05-17 2003-07-15 Conjuchem, Inc. Long lasting insulinotropic peptides
US20060009377A1 (en) * 1999-05-17 2006-01-12 Conjuchem, Inc. Long lasting synthetic glucagon like peptide (GLP-1)
US20040127398A1 (en) * 1999-05-17 2004-07-01 Conjuchem, Inc. Long lasting synthetic glucagon like peptide (GLP-1)
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20020049153A1 (en) * 1999-05-17 2002-04-25 BRIDON Dominique P. Long lasting insulinoptropic peptides
US20060135426A1 (en) * 1999-05-17 2006-06-22 Conjuchem, Inc. Long lasting synthetic glucagon like peptide (GLP-1)
US20050176643A1 (en) * 1999-05-17 2005-08-11 Conjuchem, Inc. Anti-obesity agents
US20060135428A1 (en) * 1999-05-17 2006-06-22 Bridon Dominique P Long lasting anti-angiogenic peptides
US20060058235A1 (en) * 1999-05-17 2006-03-16 Conjuchem, Inc. Long lasting synthetic glucagon like peptide (GLP-1)
US20050070475A1 (en) * 1999-05-17 2005-03-31 Conjuchem, Inc. Long lasting fusion peptide inhibitors of viral infection
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US20060233707A1 (en) * 1999-06-09 2006-10-19 Felix Kratz Process for producing an injectable medicament preparation
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US7041798B1 (en) * 1999-07-14 2006-05-09 Biotest Pharma Gmbh Method for the chromatographic fractionation of plasma or serum, preparations, so obtained, and their use
US7105508B1 (en) * 1999-08-09 2006-09-12 Abbott Gmbh & Co. Kg Integrin receptors antagonists
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US20040156859A1 (en) * 1999-09-07 2004-08-12 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) * 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
US20050187159A1 (en) * 1999-09-10 2005-08-25 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7256253B2 (en) * 1999-09-10 2007-08-14 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US20040138100A1 (en) * 1999-10-15 2004-07-15 Conjuchem, Inc. Long lasting synthetic glucagon like peptide (GLP-1)
US6887849B2 (en) * 1999-10-15 2005-05-03 Conjuchem, Inc. Long lasting synthetic glucagon-like peptide {GLP-1}
US20030108567A1 (en) * 1999-10-15 2003-06-12 BRIDON Dominique P. Long lasting synthetic glucagon-like peptide {GLP-1}
US20020003999A1 (en) * 2000-03-09 2002-01-10 Claus Bonde Discharge and stacker device
US6905688B2 (en) * 2000-04-12 2005-06-14 Human Genome Sciences, Inc. Albumin fusion proteins
US6706689B2 (en) * 2000-05-19 2004-03-16 Amylin Pharmaceuticals, Inc. Treatment of acute coronary syndrome with GLP-1
US6894024B2 (en) * 2000-10-20 2005-05-17 Amylin Pharmaceuticals, Inc. Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
US20030073630A1 (en) * 2001-02-02 2003-04-17 BRIDON Dominique P. Long lasting growth hormone releasing factor derivatives
US7112567B2 (en) * 2001-02-16 2006-09-26 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
US20060217304A1 (en) * 2001-02-16 2006-09-28 Bridon Dominique P Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
US20050065075A1 (en) * 2001-05-31 2005-03-24 Erickson John W. Long lasting fusion peptide inhibitors for hiv infection
US6861236B2 (en) * 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070269863A1 (en) * 2005-12-22 2007-11-22 Bridon Dominique P Process for the production of preformed conjugates of albumin and a therapeutic agent

Also Published As

Publication number Publication date
CN1956998B (en) 2012-12-12
TNSN06340A1 (en) 2008-02-22
EP1745078A1 (en) 2007-01-24
US20050267293A1 (en) 2005-12-01
HK1136305A1 (en) 2010-10-15
ZA200608475B (en) 2007-11-28
BRPI0510117A (en) 2007-09-25
MXPA06012260A (en) 2006-12-15
US7307148B2 (en) 2007-12-11
ES2328591T3 (en) 2009-11-16
AT473244T (en) 2010-07-15
EP2230257A1 (en) 2010-09-22
RS20060578A (en) 2008-11-28
AU2005235634B2 (en) 2011-10-20
SI1745078T1 (en) 2009-12-31
AT433999T (en) 2009-07-15
EP2100904B1 (en) 2010-07-07
EA011168B1 (en) 2009-02-27
CN1956998A (en) 2007-05-02
NO20065037L (en) 2007-01-11
ES2347902T3 (en) 2010-11-22
MA28587B1 (en) 2007-05-02
HRP20060362A2 (en) 2007-03-31
HK1096102A1 (en) 2009-12-11
CA2564031A1 (en) 2005-11-03
PT2100904E (en) 2010-09-24
EA200601959A1 (en) 2007-04-27
IL178369D0 (en) 2007-02-11
EP1745078B1 (en) 2009-06-17
DE602005022239D1 (en) 2010-08-19
US20120022234A1 (en) 2012-01-26
JP2007535507A (en) 2007-12-06
EP2100904A1 (en) 2009-09-16
AU2005235634A1 (en) 2005-11-03
DE602005014969D1 (en) 2009-07-30
EP1745078A4 (en) 2007-08-01
PT1745078E (en) 2009-09-17
DK2100904T3 (en) 2010-11-08
WO2005103087A1 (en) 2005-11-03
DK1745078T3 (en) 2009-10-26

Similar Documents

Publication Publication Date Title
JP4037174B2 (en) Production of high purity albumin
US5478805A (en) Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US9061067B2 (en) Polypeptide protracting tags
US7893017B2 (en) Protracted GLP-1 compounds
ES2322945T5 (en) Methods for protein purficación
Bickel et al. Delivery of peptides and proteins through the blood–brain barrier
EP1799711B1 (en) Protracted exendin-4 compounds
US8722620B2 (en) Insulin derivatives
CN101765608B (en) New albumin combined compositions, methods and uses
Li et al. In vitro protein refolding by chromatographic procedures
RU2623160C9 (en) Composition of delivery system based on conjugate for rna-interference polynucleotide delivery to liver cell and process for its preparation
US7906482B2 (en) Anti-obesity agents
US20090076237A1 (en) Factor VIII Polymer Conjugates
ES2548393T3 (en) Insulin derivative
Pfister et al. Process for protein PEGylation
EP0624195B1 (en) Novel biologically active polypeptides, preparation thereof and pharmaceutical composition containing said polypeptides
JP5787757B2 (en) Fgfr extracellular domain acidic region muteins
US20030171535A1 (en) Peptide derivatives
Ueda et al. Current and prospective applications of metal ion–protein binding
US20180289823A1 (en) N-Terminal Polysialylation
US20070093417A1 (en) Novel GLP-1 analogues linked to albumin-like agents
Cromwell et al. Protein aggregation and bioprocessing
US8053561B2 (en) Pegylated factor VIII
KR101241862B1 (en) Novel glp-1 derivatives
Seely et al. Use of ion-exchange chromatography and hydrophobic interaction chromatography in the preparation and recovery of polyethylene glycol-linked proteins

Legal Events

Date Code Title Description
AS Assignment

Owner name: 4523482 CANADA INC, CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONJUCHEM BIOTECHNOLOGIES INC. (CANADIAN CORPORATION NUMBER 6513590);REEL/FRAME:023794/0476

Effective date: 20091006

Owner name: CONJUCHEM BIOTECHNOLOGIES, INC., CANADA

Free format text: CHANGE OF NAME;ASSIGNOR:4523482 CANADA INC.;REEL/FRAME:023511/0734

Effective date: 20090825

AS Assignment

Owner name: 4523482 CANADA INC. (CANADIAN CORPORATION NUMBER 4

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONJUCHEM BIOTECHNOLOGIES INC. (CANADIAN CORPORATION NUMBER 6513590);REEL/FRAME:023511/0770

Effective date: 20091006

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: ADVANCED DIAGNOSTICS AND DISCOVERY, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONJUCHEM BIOTECHNOLOGIES INC.;REEL/FRAME:025198/0735

Effective date: 20100823

AS Assignment

Owner name: CONJUCHEM, LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ADVANCED DIAGNOSTICS AND DISCOVERY;REEL/FRAME:026157/0022

Effective date: 20110218